|
| 35093516 | Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. | Annals of Oncology | 2022 |
| 34861374 | Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3Â trial. | Annals of Oncology | 2022 |
| 34764307 | Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. | NPJ Breast Cancer | 2021 |
| 34243076 | Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial. | European Journal of Cancer | 2021 |
| 34131001 | Relevance of Platinum-free Interval and <i>BRCA</i> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<i>BRCA</i> Advanced Breast Cancer (BROCADE3 Crossover). | Clin Cancer Res | 2021 |
| 33823285 | Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study. | Journal of Thoracic Oncology | 2021 |
| 33652156 | A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. | J Thorac Oncol | 2021 |
| 33599688 | Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial. | JAMA Oncol | 2021 |
| 34917174 | Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline / mutations and hormone receptor status from the phase-3 BROCADE3 trial. | Therapeutic Advances in Medical Oncology | 2021 |
| 34549181 | Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin. | Neurooncol Adv | 2021 |
| 32861273 | Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet Oncology, The | 2020 |
| 31913413 | Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial. | JAMA Surgery | 2020 |
| 31926787 | Corrigendum to "Investigation of biaryl heterocycles as inhibitors of Wee1 kinase" [Bioorg. Med. Chem. Lett. 29 (2019) 1481-1486]. | Bioorganic and Medicinal Chemistry Letters | 2020 |
| 31606288 | Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial. | European Journal of Surgical Oncology | 2020 |
| 30796037 | Comparison of Biomarker Assays for <i>EGFR</i>: Implications for Precision Medicine in Patients with Glioblastoma. | Clin Cancer Res | 2019 |
| 29982805 | Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. | Neuro Oncol | 2019 |
| 30429212 | PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow. | Molecular Cancer Research | 2019 |
| 29501363 | Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. | Lancet Oncology, The | 2018 |
| 28135237 | The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex. | Nat Chem Biol | 2017 |
| 28468779 | Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors. | Molecular Cancer Therapeutics | 2017 |
| 28853738 | Erratum: The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex. | Nat Chem Biol | 2017 |
| 28610984 | SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT). | Bioorganic and Medicinal Chemistry Letters | 2017 |
| 29075855 | Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. | Cancer Chemother Pharmacol | 2017 |
| 27739325 | A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. | Future Oncol | 2017 |
| 26101576 | Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2. | ACS Med Chem Lett | 2015 |
| 25589931 | Pyrimidine-based tricyclic molecules as potent and orally efficacious inhibitors of wee1 kinase. | ACS Medicinal Chemistry Letters | 2015 |
| 26217019 | Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors. | Molecular Cancer Research | 2015 |
| 24900801 | Discovery and development of potent and selective inhibitors of histone methyltransferase g9a. | ACS Medicinal Chemistry Letters | 2014 |
| 22128301 | Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. | Clinical Cancer Research | 2012 |
| 21284988 | Amino acid signaling to mTOR mediated by inositol polyphosphate multikinase. | Cell Metab | 2011 |
| 21220345 | Inositol polyphosphate multikinase is a physiologic PI3-kinase that activates Akt/PKB. | Proc Natl Acad Sci U S A | 2011 |
| 21145457 | Inositol pyrophosphates inhibit Akt signaling, thereby regulating insulin sensitivity and weight gain. | Cell | 2010 |
| 19193859 | Glutamatergic regulation of serine racemase via reversal of PIP2 inhibition. | Proceedings of the National Academy of Sciences of the United States of America | 2009 |
| 18455988 | Pirt, a phosphoinositide-binding protein, functions as a regulatory subunit of TRPV1. | Cell | 2008 |
| 17434125 | The eukaryotic translation initiation factors eIF1 and eIF1A induce an open conformation of the 40S ribosome. | Molecular Cell | 2007 |
| 17332751 | N- and C-terminal residues of eIF1A have opposing effects on the fidelity of start codon selection. | EMBO J | 2007 |
| 17504939 | Dissociation of eIF1 from the 40S ribosomal subunit is a key step in start codon selection in vivo. | Genes Dev | 2007 |
| 17189426 | Intragenic suppressor mutations restore GTPase and translation functions of a eukaryotic initiation factor 5B switch II mutant. | Molecular and Cellular Biology | 2007 |
| 16380131 | Communication between eukaryotic translation initiation factors 5 and 1A within the ribosomal pre-initiation complex plays a role in start site selection. | Journal of Molecular Biology | 2006 |
| 16246727 | Pi release from eIF2, not GTP hydrolysis, is the step controlled by start-site selection during eukaryotic translation initiation. | Molecular Cell | 2005 |
| 15664195 | A conformational change in the eukaryotic translation preinitiation complex and release of eIF1 signal recognition of the start codon. | Molecular Cell | 2005 |
| 12860115 | Communication between eukaryotic translation initiation factors 1 and 1A on the yeast small ribosomal subunit. | Journal of Molecular Biology | 2003 |
| 12008673 | Development and characterization of a reconstituted yeast translation initiation system. | RNA | 2002 |
| 12507428 | Uncoupling of initiation factor eIF5B/IF2 GTPase and translational activities by mutations that lower ribosome affinity. | Cell | 2002 |
| 11602568 | Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. | Journal of Biological Chemistry | 2001 |
| 11100123 | The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. | Nat Med | 2000 |
| 10982360 | Template/primer requirements and single nucleotide incorporation by hepatitis C virus nonstructural protein 5B polymerase. | Journal of Virology | 2000 |